左旋多巴与恩他卡朋治疗帕金森病的临床研究

Clinical study of levodopa and entacapone in the treatment of Parkinson's disease

目的:探究左旋多巴联合恩他卡朋治疗帕金森病的临床疗效以及应用价值。方法:收治帕金森病患者共62例,随机均分为联合组(采用左旋多巴联合恩他卡朋治疗)和左旋组(采用左旋多巴治疗),观察两组患者白细胞介素6(IL-6)、白细胞介素10(IL-10)、白细胞介素1β(IL-1β),肿瘤坏死因子α(TNF-α)水平,观察治疗后疗效以及UPDRS-III和Webster评分。结果:联合组患者的治疗有效率96.8%,显著高于左旋组的71.0%,差异具有统计学意义(χ2=7.63,P<0.05)。左旋组治疗后IL-6、IL-10、TNF-α、IL-1β水平显著高于联合组,差异具有统计学意义(P<0.05)。左旋组患者治疗后UPDRS-Ⅲ评分和Webster评分均高于联合组,差异具有统计学意义(P<0.05)。结论:左旋多巴联合恩他卡朋能够有效治疗帕金森病,控制病情,改善症状,提高患者生命质量。

Objective:To investigate the curative effect and application value of levodopa and entacapone in the treatment ofParkinson's disease.Methods:62patients with Parkinson's disease were selected.They were randomly divided into the combinedgroup(with levodopa combined with entacapone treatment)and the levoversion(levodopa treatment).The levels of interleukin6(IL-6),interleukin10(IL-10),interleukin1β(IL-1β)and tumor necrosis factor alpha(TNF-α)levels were observed in twogroups of patients.The curative effect,UPDRS-Ⅲand Webster scores were observed after treatment.Results:The effective rate oftreatment in the combined group was96.8%,significantly higher than that in the levoversion group(71%),and the differences werestatistically significant(χ2=7.63,P<0.05).The level of IL-6,IL-10,TNF-α,IL-1βof the levoversion group weresignificantly higher than that of the combined group,and the difference was statistically significant(P<0.05).UPDRS-Ⅲscoreand Webster score of levoversion group after treatment were higher than those in the combined group,and differences werestatisticallt significant(P<0.05).Conclusion:Levodopa combined with entacapone to treat Parkinson's disease,effective control ofthe disease,improve symptoms,improve the quality of life.